| Literature DB >> 35326088 |
Luca Pozzetti1, Francesca Ferrara2, Ludovica Marotta1, Sandra Gemma1, Stefania Butini1, Mascia Benedusi2, Fabio Fusi1, Amer Ahmed3, Serena Pomponi4, Stefano Ferrari5, Matteo Perini6, Anna Ramunno7, Giacomo Pepe7, Pietro Campiglia7, Giuseppe Valacchi8,9,10, Gabriele Carullo1, Giuseppe Campiani1.
Abstract
Extra virgin olive oil (EVOO) is the typical source of fats in the Mediterranean diet. While fatty acids are essential for the EVOO nutraceutical properties, multiple biological activities are also due to the presence of polyphenols. In this work, autochthonous Tuscany EVOOs were chemically characterized and selected EVOO samples were extracted to obtain hydroalcoholic phytocomplexes, which were assayed to establish their anti-inflammatory and vasorelaxant properties. The polar extracts were characterized via 1H-NMR and UHPLC-HRMS to investigate the chemical composition and assayed in CaCo-2 cells exposed to glucose oxidase or rat aorta rings contracted by phenylephrine. Apigenin and luteolin were found as representative flavones; other components were pinoresinol, ligstroside, and oleuropein. The extracts showed anti-inflammatory and antioxidant properties via modulation of NF-κB and Nrf2 pathways, respectively, and good vasorelaxant activity, both in the presence and absence of an intact endothelium. In conclusion, this study evaluated the nutraceutical properties of autochthonous Tuscany EVOO cv., which showed promising anti-inflammatory and vasorelaxant effects.Entities:
Keywords: CaCo-2 cells; NF-κB; Nrf2; food origin; luteolin; oleuropein; olive oil; traceability quality
Year: 2022 PMID: 35326088 PMCID: PMC8944769 DOI: 10.3390/antiox11030437
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Geographical distribution of the samples of EVOO.
Quantification of the main components in EVOO samples.
| EVOO Samples | Cultivars | Acidity | Oleic Acid (%) | Linoleic Acid (%) | TPC (mg/kg) | Biophenols (mg/kg) | Tocopherols (mg/kg) | Peroxides (meq O2/kg) |
|---|---|---|---|---|---|---|---|---|
|
| 0.15 | 75.48 | 6.28 | 703 | 664 | 298 | 7.70 | |
|
| 0.11 | 76.68 | 5.86 | 517 | 405 | 164 | 8.00 | |
|
| 0.12 | 75.72 | 6.01 | 632 | 451 | 260 | 7.20 | |
|
| 0.11 | 76.92 | 5.75 | 467 | 321 | 228 | 6.80 | |
|
| 0.11 | 77.04 | 5.95 | 406 | 314 | 221 | 6.50 | |
|
| 0.14 | 77.54 | 5.63 | 474 | 293 | 228 | 8.40 | |
|
| 0.10 | 76.18 | 5.99 | 547 | 345 | 223 | 9.30 | |
|
| 0.11 | 75.96 | 6.07 | 627 | 560 | 270 | 7.30 | |
|
| 0.13 | 77.34 | 5.78 | 465 | 372 | 167 | 8.50 | |
|
| 0.11 | 76.45 | 5.73 | 713 | 477 | 446 | 5.30 | |
|
| 0.08 | 76.47 | 5.68 | 444 | 290 | 291 | 6.20 | |
|
| 0.09 | 77.20 | 5.75 | 586 | 405 | 207 | 5.70 | |
|
| 0.09 | 77.14 | 5.40 | 410 | 227 | 238 | 7.10 | |
|
| 0.09 | 75.75 | 5.98 | 602 | 434 | 254 | 6.30 | |
|
| 0.13 | 75.53 | 6.34 | 681 | 553 | 239 | 4.90 | |
|
| 0.12 | 75.83 | 6.16 | 540 | 380 | 216 | 6.20 | |
|
| 0.10 | 77.09 | 5.66 | 440 | 243 | 222 | 7.90 | |
|
| 0.10 | 76.44 | 5.98 | 529 | 385 | 261 | 7.00 |
Stable isotopic ratios of six EVOO samples.
| EVOO | Cultivars | Altitude | 13C/12C (δ13C) | 18O/16O (δ18O) | 2H/1H (δ2H) |
|---|---|---|---|---|---|
|
| 450 | −30.2‰ | 23.2‰ | −146‰ | |
|
| 350 | −30.9‰ | 22.8‰ | −149‰ | |
|
| 300 | −30.1‰ | 23.2‰ | −150‰ | |
|
| 300 | −30.5‰ | 22.1‰ | −148‰ | |
|
| 330 | −29.6‰ | 23.5‰ | −149‰ | |
|
| 600 | −30.5‰ | 23.2‰ | −150‰ |
1H NMR qualitative analysis of the major components in EVOO extracts OE_05, OE_10, and OE_15.
| Compound | Assignment | 1H (ppm) | Multiplicity | Samples | ||
|---|---|---|---|---|---|---|
| OE_05 | OE_10 | OE_15 | ||||
| Oleuropein | CHOH | 9.49 | m | + | + | + |
| Oleocanthal | CHO | 9.23 | s | + | + | + |
| CH=CH | 7.54 | d | + | + | + | |
| Tyrosol (total) | - | 7.08–6.96 | not assigned | + | + | + |
| Hydrotyrosol | - | 6.54–6.41 | not assigned | + | + | + |
| Carotenoids (total) | CH | 6.68 | m | + | + | + |
| Luteolin | C6-H | 6.18 | m | − | + | − |
| Ligstroside | - | 4.20–4.00 | not assigned | + | + | + |
| Pinoresinol | OCH3 | 3.75 | s | + | − | + |
| 1-Acetoxypinoresinol | OCH3 | 3.76 | s | − | + | + |
| Campesterol | CH3–18 | 0.70 | s | + | + | + |
| β-Sitosterol | CH3–18 | 0.68 | s | + | + | + |
Note: (+) presence, (−) absence.
UHPLC-HRMS qualitative analysis of the major components in EVOO extracts OE_05, OE_10, and OE_15.
| Peak | Retention | [M-H]- | MS/MS | Error | Proposed | Molecular |
|---|---|---|---|---|---|---|
| 00 | 3.07 ± 0.01 | 153.0556 | 123.4023; 95.4011 | −0.65 | 3-Hydroxytyrosol | C8H10O3 |
| 0 | 4.46 ± 0.03 | 137.0602 | 112.0045 | −4.37 | Tyrosol | C8H10O2 |
| 1 | 6.47 ± 0.03 | 335.1093 | 199.0564; 155.0665 | −8.95 | Oleacinic acid | C17H20O7 |
| 2 | 8.77 ± 0.02 | 319.1168 | 181.0452; 199.0551 | −5.95 | Oleocanthalic acid | C17H20O6 |
| 3 | 9.41 ± 0.02 | 285.0410 | 175.0382; 199.0373 | 2.10 | Luteolin | C15H10O6 |
| 4 | 9.57 ± 0.11 | 357.1368 | 136.0393; 342.0891 | 7.00 | Pinoresinol | C20H21O6 |
| 5 | 10.14 ± 0.19 | 377.1205 | 275.0829; 149.0197; 139.0074 | 0.7 | Oleuropein aglycone | C19H21O8 |
| 6 | 10.32 ± 0.04 | 377.1205 | 275.0831; 149.0199; 139.0076 | 0.9 | Oleuropein aglycone Isomer II | C19H21O8 |
| 7 | 10.51 ± 0.02 | 269.0414 | 225.0481; 150.0228; 117.0289 | 5.7 | Apigenin | C15H10O5 |
| 8 | 10.67 ± 0.16 | 377.1205 | 275.0829; 149.0197; 139.0074 | −4.4 | Oleuropein aglycone Isomer III | C19H21O8 |
| 9 | 10.90 ± 0.10 | 377.1201 | 275.0842; 149.0174; 139.0010 | −5.4 | Oleuropein aglycone Isomer IV | C19H21O8 |
| 10 | 11.42 ± 0.19 | 361.1250 | 291.0780; 259.0926 | −4.1 | Ligstroside-aglycone | C19H22O7 |
| 11 | 12.21 ± 0.02 | 361.1242 | 291.0801; 259.0865 | −9.0 | Ligstroside-aglycone Isomer II | C19H22O7 |
| 12 | 12.63 ± 0.02 | 361.1271 | 291.0808; 259.0909 | −4.2 | Ligstroside-aglycone Isomer III | C19H22O7 |
Figure 2Quantification of luteolin and apigenin in EVOO extracts (OE).
Figure 3CaCo-2 cell viability evaluated by MTT assay after 24 h of pre-treatment with olive oil compound extracts OE_05 and OE_10 at different doses ranging from 2 to 50 μg/mL. (a) Vehicle 1 represents the DMSO concentration of OE_05 or OE_10 2 μg/mL solution. (b) Vehicle 2 represents DMSO concentration of OE_05 or OE_10 50 μg/mL solution. Ctrl represents untreated cells. Data are given as means ± SD, representative of three independent experiments with at least three technical replicates each time.
Figure 4(a) H2O2 levels in media of CaCo-2 cells treated with 20 μg/mL OE_05 or OE_10 for 24 h and exposed to GO 0.5 U/mL for 1 h (T0, T30′, T1). (b) Immunofluorescence staining of DAPI (blue) and Nrf2 (red), 0 and 1 h post-GO exposure in CaCo-2 cells pre-treated with 20 μg/mL of OE_05 or OE_10 for 24 h. Original magnification at 40x; scale bar = 40μm. The immunofluorescent signal was semiquantified by using ImageJ software (National Institutes of Health, Bethesda, MD) and the quantification graphs are displayed in the bottom panel. Transcript levels of GPx1 (c) and NQO1 (d) measured using qRT-PCR 6 h post-GO exposure in CaCo-2 cells pre-treated with EVOO extracts for 24 h. Data are the results of the averages of at least three different experiments, # p < 0.05, ## p < 0.01, ### p < 0.001 GO ± OE_05 or OE_10 vs. ctrl and ¥ p < 0.05, ¥¥ p < 0.01, ¥¥¥ p < 0.001 GO + OE_05 or OE_10 vs. GO as assessed by one-way ANOVA.
Figure 5(a) Immunofluorescence staining of DAPI (blue) and NF-κB (green) in CaCo-2 cells treated with 20 μg/mL of OE_05 or OE_10 for 24 h and exposed to GO 0.5 U/mL for 1 h. Timepoints at 0 and 1 h post-exposure (T0, T1). Original magnification at 40x; scale bar = 40μm. The immunofluorescent signal was semiquantified using ImageJ software (National Institutes of Health, Bethesda, MD) and the quantification graphs are displayed in the bottom panel. Transcript levels of IL-6 (b) and COX2 (c) measured using qRT-PCR 6 h post-GO-exposure in CaCo-2 cells pre-treated with EVOO extracts for 24 h. Data are the results of the averages of at least three different experiments, ## p < 0.01, ### p < 0.001 GO ± OE_05 or OE_10 vs. ctrl and ¥ p < 0.05, ¥¥ p < 0.01, ¥¥¥ p < 0.001 GO + OE_05 or OE_10 vs. GO as assessed by one-way ANOVA.
Figure 6Effect of the EVOO extracts on phenylephrine-induced contraction of rat aorta rings. Concentration-response curves of (a) OE_05, (b) OE_10, and (c) OE_15 on endothelium-denuded (-endothelium) or endothelium-intact (+endothelium) preparations pre-contracted by 0.3 µM phenylephrine (phe). (d) The effects of the vehicle DMSO are shown. In the ordinate scale, the response is reported as a percentage of the initial tension induced by phenylephrine, taken as 100%. Data are means ± SEM (n = 5–9).